Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044013 | 0.78 | — | — | |
| SCHEMBL5038754 | 0.74 | RAB9A (0.36) | GAAMAPTHSD17B10CYP1A2 | |
| SCHEMBL9407864 | 0.73 | JAK2 (0.45) | GAAMAPTALOX15HSD17B10CYP1A2 | |
| SCHEMBL1937448 | 0.73 | PARP1 (0.47) | PDE3BPDE3A | |
| SCHEMBL517634 | 0.72 | ALOX15 (0.52) | GAAMAPTALOX15HSD17B10NPSR1 | |
| SCHEMBL517635 | 0.72 | ALOX15 (0.52) | GAAMAPTALOX15HSD17B10NPSR1 | |
| SCHEMBL29749158 | 0.72 | ALOX15 (0.52) | GAAMAPTALOX15HSD17B10NPSR1 | |
| SCHEMBL6137103 | 0.71 | MAPT (0.48) | GAAMAPTALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL1953522 | 0.69 | CYP11B2 (0.39) | CYP1A2 | |
| SCHEMBL31095197 | 0.69 | GAA (0.58) | GAAMAPTCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | GAA 951/4885MAPT 3282/4885ALOX15 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.